

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5195709

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GILEAD SCIENCES, INC.	10/18/2018
RECEIVING PARTY DATA	
Name:	SIERRA ONCOLOGY, INC.
Street Address:	46701 COMMERCE CENTER DRIVE
City:	PLYMOUTH
State/Country:	MICHIGAN
Postal Code:	48170
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14736690
CORRESPONDENCE DATA	
Fax Number:	(650)938-5200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(415) 875-2316
Email:	sellenburg@fenwick.com
Correspondent Name:	SUSAN T. HUBL
Address Line 1:	FENWICK & WEST LLP
Address Line 2:	801 CALIFORNIA STREET
Address Line 4:	MOUNTAIN VIEW, CALIFORNIA 94041
ATTORNEY DOCKET NUMBER:	31899-41381/US
NAME OF SUBMITTER:	SUSAN T. HUBL, REG. 47668
SIGNATURE:	/Susan T. Hubl/
DATE SIGNED:	10/18/2018
Total Attachments: 2	
source=41381 US Corporate to Corporate Assignment Gilead to Sierra#page1.tif	
source=41381 US Corporate to Corporate Assignment Gilead to Sierra#page2.tif	

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **Gilead Sciences, Inc.**, a Delaware Corporation, having a place of business at 333 Lakeside Drive, Foster City, California 94404 ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to **Sierra Oncology, Inc.**, a Delaware Corporation, having a place of business at Michigan Life Science and Innovation Center, 46701 Commerce Center Drive, Plymouth, Michigan 48170 ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional or non-provisional application filed under 35 U.S.C. § 111, design application filed under 35 U.S.C. § 171, Registered Community Designs, international application filed according to the Patent Cooperation Treaty (PCT), U.S. national phase application filed under 35 U.S.C. § 371, and any patents issuing thereon ("PATENT RIGHTS"):

COUNTRY	APPLICATION NUMBER	FILING DATE	TITLE	PATENT NUMBER	ISSUE DATE
U.S.	14/736,690	June 11, 2015	N-(Cyanomethyl)-4-(2-(4-Morpholinophenylamino)Pyrimidin-4-YL) Benzamide	9,469,613	October 18, 2016

and;

2. The entire worldwide right, title, and interest in and to:
(a) the PATENT RIGHTS, including any right of priority; (b) any provisional, divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titled and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, transferee, assignee, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

Title:	N-(Cyanomethyl)-4-(2-(4-Morpholinophenylamino)Pyrimidin-4-YL) Benzamide		
Filed:	June 11, 2015	Attorney Docket #:	31899-41381/US
Application #:	14/736,690	Client Ref #:	SR-1050US1

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.


Duly Authorized Representative of ASSIGNOR

Signature: _____

Name: _____

Title: _____

Date of Signature: _____



 J. Elin Hartrum

 Vice President, Patents

 October 18, 2018
